UKE cohort
UKE cohort是卵巢癌转录组数据集，包含181例RNA测序及临床数据，用于识别贝伐珠单抗治疗反应生物标志物。
基本信息
资源简介
UKE cohort是由汉堡大学医学中心创建的卵巢癌转录组数据集，包含181例患者的RNA测序数据及临床信息（如肿瘤分期、手术结果），旨在通过基因表达谱分析识别贝伐珠单抗治疗反应的潜在生物标志物，支持卵巢癌个性化治疗。
下载信息
注册下载
Tips: 该数据集需要在对应的数据源网站注册通过后，才能进行数据下载，注册有对应要求，或者需要收费。
暂未开放公开下载
Tips: 该数据集属于公开下载，应该可以免费公开下载。
免登录有偿下载
Tips: 该数据集 Qianfanghub 可以协助提供有偿下载服务，注意，服务不针对数据相关产权，只是技术服务费。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放千方医数集，医疗数据集部分，是为社区服务的公开医疗数据集搜索引擎，并不存储或者下载原始的任何数据。 如果您有其他医疗数据需求，可以和客服联系，或者下工单。我们有强大的三甲医疗机构帮助您提供个性化的医疗数据定制、采集、标注服务。
使用方式
数据集说明
UKE cohort 对应论文数据集（arXiv 预印本）。
数据获取指引
- 打开论文页面获取作者与项目信息：https://arxiv.org/abs/2501.04869v1
- 论文 Data Availability / Code Availability 章节标注了数据实际托管位置；
- 获取到实际数据链接后，按对应平台标准方式下载。
论文摘要：Abstract:The standard of care for ovarian cancer comprises cytoreductive surgery, followed by adjuvant platinum-based chemotherapy plus taxane therapy and maintenance therapy with the antiangiogenic compound bevacizumab and/or a PARP inhibitor. Nevertheless, there is currently no clear clinical indication for the use of bevacizumab, highlighting the urgent need for biomarkers to assess the response to bevacizumab. In the present study, based on a novel RNA-seq dataset (n=181) and a previously published microarray-based dataset (n=377), we have identified an expression signature potentially associated with benefit from bevacizumab addition and assumed to reflect cancer stemness acquisition driven by activation of CTCFL. Patients with this signature demonstrated improved overall survival when bevacizumab was added to standard chemotherapy in both novel (HR=0.41(0.23-0.74), adj.p-value=7.70e-03) and previously published cohorts (HR=0.51(0.34-0.75), adj.p-value=3.25e-03), while no significant differences in survival explained by treatment were observed in patients negative for this signature. In addition to the CTCFL signature, we found several other reproducible expression signatures which may also represent biomarker candidates not related to established molecular subtypes of ovarian cancer and require further validation studies based on additional RNA-seq data.
精度瓶颈？数据缺失？
当前公开数据无法满足您的算法精度？千方提供针对 卵巢癌 的高质量、多模态真实临床数据定制解决方案。
